Evidence map›Paper›PMID 38612630›Full record

ArticleInternational journal of molecular sciences2024

Difference between Keratinized- and Non-Keratinized-Originating Epithelium in the Process of Immune Escape of Oral Squamous Cell Carcinoma.

Yoshiaki Kitsukawa, Chonji Fukumoto, Toshiki Hyodo, Yuske Komiyama, Ryo Shiraishi, Aya Koike, Shuma Yagisawa, Yosuke Kunitomi, Tomonori Hasegawa, Wataru Kotani and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Yoshiaki KitsukawaDepartment of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, Shimo-Tsuga, Mibu 321-0293, Tochigi, Japan.
Chonji FukumotoDepartment of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, Shimo-Tsuga, Mibu 321-0293, Tochigi, Japan.ORCID 0000-0002-5160-6892
Toshiki HyodoDepartment of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, Shimo-Tsuga, Mibu 321-0293, Tochigi, Japan.
Yuske KomiyamaDepartment of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, Shimo-Tsuga, Mibu 321-0293, Tochigi, Japan.
Ryo ShiraishiDepartment of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, Shimo-Tsuga, Mibu 321-0293, Tochigi, Japan.
Aya KoikeDepartment of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, Shimo-Tsuga, Mibu 321-0293, Tochigi, Japan.
Shuma YagisawaDepartment of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, Shimo-Tsuga, Mibu 321-0293, Tochigi, Japan.
Yosuke KunitomiDepartment of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, Shimo-Tsuga, Mibu 321-0293, Tochigi, Japan.
Tomonori HasegawaDepartment of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, Shimo-Tsuga, Mibu 321-0293, Tochigi, Japan.
Wataru KotaniDepartment of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, Shimo-Tsuga, Mibu 321-0293, Tochigi, Japan.
Kazuyuki IshidaDepartment of Diagnostic Pathology, Dokkyo Medical University School of Medicine, Shimo-Tsuga, Mibu 321-0293, Tochigi, Japan.ORCID 0000-0002-2804-4588
Takahiro WakuiDepartment of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, Shimo-Tsuga, Mibu 321-0293, Tochigi, Japan.
Hitoshi KawamataDepartment of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, Shimo-Tsuga, Mibu 321-0293, Tochigi, Japan.
Dokkyo Medical University · JPKamituga General Hospital · JPSapporo Kosei General Hospital · JPUtsunomiya University · JP

Funding

Dokkyo Medical University 2372JSPS KAKENHI JP22K10179JSPS KAKENHI JP22K17214
6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs), including anti-programmed cell death 1 ligand 1 (PD-L1) antibodies, are significantly changing treatment strategies for human malignant diseases, including oral cancer. Cancer cells usually escape from the immune system and acquire proliferative capacity and invasive/metastatic potential. We have focused on the two immune checkpoints, PD-1/PD-L1 and CD47/SIRPα, in the tumor microenvironment of oral squamous cell carcinoma (OSCC), performed a retrospective analysis of the expression of seven immune-related factors (PD-L1, PD-1, CD4, CD8, CD47, CD56 and CD11c), and examined their correlation with clinicopathological status. As a result, there were no significant findings relating to seven immune-related factors and several clinicopathological statuses. However, the immune checkpoint-related factors (PD-1, PD-L1, CD47) were highly expressed in non-keratinized epithelium-originated tumors when compared to those in keratinized epithelium-originated tumors. It is of interest that immunoediting via immune checkpoint-related factors was facilitated in non-keratinized sites. Several researchers reported that the keratinization of oral mucosal epithelia affected the immune response, but our present finding is the first study to show a difference in tumor immunity in the originating epithelium of OSCC, keratinized or non-keratinized. Tumor immunity, an immune escape status of OSCC, might be different in the originating epithelium, keratinized or non-keratinized.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsMouth NeoplasmsB7-H1 AntigenCD47 AntigenEpitheliumHumansProgrammed Cell Death 1 ReceptorRetrospective StudiesSquamous Cell Carcinoma of Head and NeckTumor MicroenvironmentB7-H1 AntigenCD47 AntigenProgrammed Cell Death 1 ReceptorCD47immune checkpointimmune escapeoral squamous cell carcinomaprogrammed cell death 1-ligand 1 (PD-L1)programmed death receptor-1 (PD-1)tumor immunity

Identifiers

PMID38612630
PMCPMC11011939
OpenAlexW4393317457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.